High Risk Surgically Resectable Melanoma clinical trials

Explore recruiting high risk surgically resectable melanoma clinical trials.

Also recruiting in Europe

High Risk Surgically Resectable Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

High Risk Surgically Resectable Melanoma trials by city

High Risk Surgically Resectable Melanoma in Toronto High Risk Surgically Resectable Melanoma in Vancouver High Risk Surgically Resectable Melanoma in Montreal High Risk Surgically Resectable Melanoma in Calgary High Risk Surgically Resectable Melanoma in Edmonton High Risk Surgically Resectable Melanoma in Ottawa High Risk Surgically Resectable Melanoma in Winnipeg High Risk Surgically Resectable Melanoma in Quebec City High Risk Surgically Resectable Melanoma in Hamilton High Risk Surgically Resectable Melanoma in Kitchener High Risk Surgically Resectable Melanoma in London High Risk Surgically Resectable Melanoma in Halifax High Risk Surgically Resectable Melanoma in New York High Risk Surgically Resectable Melanoma in Los Angeles High Risk Surgically Resectable Melanoma in Chicago High Risk Surgically Resectable Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease